Patients with multiple myeloma enter maintenance therapy after induction chemotherapy and autologous bone marrow transplantation, and maintenance therapy drugs can be selected according to the patient’s condition. Thalidomide (Response Stop) is currently recommended for maintenance therapy at the usual dose of 100 mg per night, along with adjuvant diphosphonate therapy to improve bone destruction. Patients should undergo a comprehensive disease assessment, especially bone marrow smear and blood and urine M protein quantification and fixed electrophoresis, before entering the maintenance treatment period to determine the efficacy. Patients should have regular outpatient follow-up visits, usually every 3 months, requiring tests including: routine blood, liver and kidney function, blood calcium, serum and urine immunoglobulins, light chain quantification and fixed electrophoresis. If urine light chain is significantly elevated, 24-hour urine should be left for retesting to know the total 24-hour urine light chain. Regular checkups can help doctors detect the progress of the disease early and adjust the medication in time to avoid delaying the disease. We wish all patients a speedy recovery.